62554-90-9

Basic information

• Product Name: 4-BroMo-2,6-dinitroaniline
• Synonyms: 4-BroMo-2,6-dinitroaniline
• CAS NO: 62554-90-9
• Molecular Formula: C₆H₄BrN₃O₄
• Molecular Weight: 262.01766
• Mol File: 62554-90-9.mol
• Article Data: 6

Chemical Properties

• Melting Point: 162 °C
• Boiling Point: 360.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.991±0.06 g/cm3(Predicted)
• PKA: -6.21±0.25(Predicted)
• CAS DataBase Reference: 4-BroMo-2,6-dinitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BroMo-2,6-dinitroaniline(62554-90-9)
• EPA Substance Registry System: 4-BroMo-2,6-dinitroaniline(62554-90-9)

Safety Data

• Hazardous Substances Data: 62554-90-9(Hazardous Substances Data)

Usage

Description

4-Bromo-2,6-dinitroaniline is an organic compound characterized by the presence of a bromo group at the 4th position, and nitro groups at the 2nd and 6th positions on an aniline molecule. It is a synthetic chemical with specific properties that make it suitable for various applications in different industries.

Uses

Used in Pharmaceutical Industry:
4-Bromo-2,6-dinitroaniline is used as a reactant for the preparation of quinazolinone derivatives, which are known for their antiviral properties. These derivatives are valuable in the development of new antiviral agents to combat viral infections, making 4-Bromo-2,6-dinitroaniline an important compound in the pharmaceutical sector.

Upstream product

• 103-88-8 4-bromoacetanilide 
• 606-22-4 2,6-dinitroaniline 
• 6310-99-2 2,5-dibromo-1,3-dinitro-benzene 
• 51796-82-8 5-bromo-2-chloro-1,3-dinitro-benzene 
• 67856-76-2 4-bromo-2,6-dinitroanisole 
• 195045-44-4 (4-amino-3,5-dinitro-phenyl)-arsonic acid 
• 861557-71-3 N-ethyl-N'-(4-bromo-2,6-dinitro-phenyl)-N-nitro-urea 
• 860604-90-6 4-nitro-benzoic acid-(4-bromo-2,6-dinitro-anilide) 
• 860556-00-9 3-nitro-benzoic acid-(4-bromo-2,6-dinitro-anilide) 
• 89365-43-5 4-Brom-2,6-dinitro-phenylazid 
• 7664-41-7 ammonia 
• 7726-95-6 bromine 
• 7732-18-5 water 
• 7702-38-7 N-(4-bromophenyl)benzamide 

Downstream Products

• 40466-95-3 4-bromo-2,6-dinitrophenol 
• 84752-20-5 4-bromo-6-nitro-1,2-phenylenediamine 
• 6310-99-2 2,5-dibromo-1,3-dinitro-benzene 
• 15001-00-0 5-bromo-1,2,3-trinitro-benzene 
• 1000289-53-1 2,6-dinitro-4-pyridin-3-yl-aniline 
• 15001-01-1 2-[N'-(4-bromo-2,6-dinitro-phenyl)-N-phenyl-hydrazino]-thiazole 
• 14673-40-6 2-[N'-(4-bromo-2,6-dinitro-phenyl)-N-phenyl-hydrazino]-4-phenyl-thiazole 
• 15286-74-5 2-[N'-(4-bromo-2,6-dinitro-phenyl)-N-phenyl-hydrazino]-4,5-diphenyl-thiazole 
• 36021-27-9 N,N-Diphenyl-N'-<4-brom-2,6-dinitro-phenyl>-hydrazyl 
• 860390-47-2 4-Brom-2,6-dinitro-N,N-diphenyl-phenylhydrazin 
• 713530-84-8 N-(4-bromo-2,6-dinitro-phenyl)-acetamide 
• 713530-86-0 N-[5-bromo-2-(2-chloro-acetylamino)-3-nitro-phenyl]-2-chloro-acetamide 
• 713530-56-4 6-bromo-2-methyl-4-nitro-1H-benzimidazole 
• 1372540-00-5 1-[(2,3-dichlorophenyl)methyl]-4-fluoro-2-methyl-6-(4-morpholinyl)-1H-benzimidazole 

Relevant articles and documents

Synthesis and characterization of heterocyclic conjugated polymers containing planar benzo[c]cinnoline and tetraazapyrene structures for organic field-effect transistor application

Heterocyclic conjugated polymers BZCTVT and TAPTVT containing benzo[c]cinnoline (BZC) and tetraazapyrene (TAP), respectively, were prepared by using Stille coupling polymerization in microwave reactor. BZC and TAP act as acceptors and thiophene-vinylene-t

BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kβ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

ANTIBACTERIAL COMPOSITIONS

Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1 ; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C1-C3 alkyl; X is -C(=O)NR6-, -S(O)NR6-, -C(=O)O- or -S(=O)O- wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -Cyc, or -( C1-C3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R2 and R3 are as defined in the description.